Short Term Outcome and Associated factor Among Stroke Patien Given Trombolysis
DOI:
https://doi.org/10.23917/bik.v18i1.5547Keywords:
thrombolysis, outcome, Stroke, rTPA, PhilippinesAbstract
The study aimed to investigate the short-term outcome and associated factors among acute ischemic stroke patients given rTPA (Recombinant tissue plasminogen activator). This is a hospital-based cross-sectional retrospective study among 107 acute stroke patients given rTPA for a span of 3 years. A favorable outcome is defined as the modified Rankin Scale (MRS) 0 to 2, while a score > 2 is defined as a poor outcome. Mortality and adverse events were also documented. The majority (57%) had favorable outcomes on discharge. Initial stroke severity, stroke etiology, and presence of symptomatic Intracerebral hemorrhage (ICH) were significant factors for discharge outcome. There was no significance as to age group and as to needle time of 0-3 hours versus 3-4.5 hours. The symptomatic ICH rate is 5.6%. The overall mortality rate is 15.88% (47% due to malignant infarction, 17.6% due to symptomatic intracerebral hemorrhage (sICH), 23.52% due to basilar artery occlusion (BAO), and 11.7% due to medical causes). With a dose of 0.6mg/kg, our data indicate favorable discharge outcomes of thrombolysis. A high baseline NIHSS, cardioembolic stroke etiology, and the presence of sICH are seen in patients with poor outcomes. The rate of sICH is consistent with other literature, however with high mortality (100%). Overall mortality is high primarily due to malignant infarct. Institutions must be capacitated to address outcomes and complications of thrombolysis.
Downloads
References
Anderson, C. S., Robinson, T., Lindley, R. I., Arima, H., Lavados, P. M., Lee, T.-H., Broderick, J. P., Chen, X., Chen, G., Sharma, V. K., Kim, J. S., Thang, N. H., Cao, Y., Parsons, M. W., Levi, C., Huang, Y., Olavarría, V. V, Demchuk, A. M., Bath, P. M., … Chalmers, J. (2016). Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. The New England Journal of Medicine, 374(24), 2313–2323. https://doi.org/10.1056/NEJMoa1515510 PubMed: PMID: 27161018
Demaerschalk, B. M., Kleindorfer, D. O., Adeoye, O. M., Demchuk, A. M., Fugate, J. E., Grotta, J. C., Khalessi, A. A., Levy, E. I., Palesch, Y. Y., Prabhakaran, S., Saposnik, G., Saver, J. L., & Smith, E. E. (2016). Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 47(2), 581–641. https://doi.org/10.1161/STR.0000000000000086 PubMed: PMID: 26696642
Ghandehari, K. (2011). Barriers of thrombolysis therapy in developing countries. Stroke Research and Treatment, 2011, 686797. https://doi.org/10.4061/2011/686797 PubMed: PMID: 21603174
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., Schneider, D., von Kummer, R., Wahlgren, N., & Toni, D. (2008). Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. The New England Journal of Medicine, 359(13), 1317–1329. https://doi.org/10.1056/NEJMoa0804656 PubMed: PMID: 18815396
Ifejika-Jones, N. L., Harun, N., Mohammed-Rajput, N. A., Noser, E. A., & Grotta, J. C. (2011). Thrombolysis with intravenous tissue plasminogen activator predicts a favorable discharge disposition in patients with acute ischemic stroke. Stroke, 42(3), 700–704. https://doi.org/10.1161/STROKEAHA.110.604108 PubMed: PMID: 21293014
Lees, K. R., Emberson, J., Blackwell, L., Bluhmki, E., Davis, S. M., Donnan, G. A., Grotta, J. C., Kaste, M., von Kummer, R., Lansberg, M. G., Lindley, R. I., Lyden, P., Murray, G. D., Sandercock, P. A. G., Toni, D., Toyoda, K., Wardlaw, J. M., Whiteley, W. N., Baigent, C., … Howard, G. (2016). Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials. Stroke, 47(9), 2373–2379. https://doi.org/10.1161/STROKEAHA.116.013644 PubMed: PMID: 27507856
Morihara, R., Kono, S., Sato, K., Hishikawa, N., Ohta, Y., Yamashita, T., Deguchi, K., Manabe, Y., Takao, Y., Kashihara, K., Inoue, S., Kiriyama, H., & Abe, K. (2016). Thrombolysis with Low-Dose Tissue Plasminogen Activator 3-4.5 h After Acute Ischemic Stroke in Five Hospital Groups in Japan. Translational Stroke Research, 7(2), 111–119. https://doi.org/10.1007/s12975-016-0448-8
Navarro, J. C., Baroque, A. C. 2nd, Lokin, J. K., & Venketasubramanian, N. (2014). The real stroke burden in the Philippines. International Journal of Stroke : Official Journal of the International Stroke Society, 9(5), 640–641. https://doi.org/10.1111/ijs.12287 PubMed: PMID: 24844610
Navarro, J. C., San Jose, M. C., Collantes, E., Macrohon-Valdez, M. C., Roxas, A., Hiyadan, J., Surdilla, A., Kalbi, M., De Leon-Gacrama, F., Escabillas, C. G., & Reandelar, M. (2018). Stroke thrombolysis in the Philippines. Neurology Asia, 23(2), 115–120. https://www.neurology-asia.org/articles/neuroasia-2018-23(2)-115.pdf
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., Jauch, E. C., Kidwell, C. S., Leslie-Mazwi, T. M., Ovbiagele, B., Scott, P. A., Sheth, K. N., Southerland, A. M., Summers, D. V, & Tirschwell, D. L. (2018). 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 49(3), e46–e110. https://doi.org/10.1161/STR.0000000000000158 PubMed: PMID: 29367334
Putaala, J., Metso, T. M., Metso, A. J., Mäkelä, E., Haapaniemi, E., Salonen, O., Kaste, M., & Tatlisumak, T. (2009). Thrombolysis in young adults with ischemic stroke. Stroke, 40(6), 2085–2091. https://doi.org/10.1161/STROKEAHA.108.541185 PubMed: PMID: 19372446
Sandercock, P., Wardlaw, J. M., Lindley, R. I., Dennis, M., Cohen, G., Murray, G., Innes, K., Venables, G., Czlonkowska, A., Kobayashi, A., Ricci, S., Murray, V., Berge, E., Slot, K. B., Hankey, G. J., Correia, M., Peeters, A., Matz, K., Lyrer, P., … Arauz, A. (2012). The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet (London, England), 379(9834), 2352–2363. https://doi.org/10.1016/S0140-6736(12)60768-5 PubMed: PMID: 22632908
Saposnik, G., Gladstone, D., Raptis, R., Zhou, L., & Hart, R. G. (2013). Atrial fibrillation in ischemic stroke: predicting response to thrombolysis and clinical outcomes. Stroke, 44(1), 99–104. https://doi.org/10.1161/STROKEAHA.112.676551 PubMed: PMID: 23168456
Suwanwela, N. C., & Poungvarin, N. (2016). Stroke burden and stroke care system in Asia. Neurology India, 64 Suppl, S46-51. https://doi.org/10.4103/0028-3886.178042 PubMed: PMID: 26954968
Tissue plasminogen activator for acute ischemic stroke. (1995). The New England Journal of Medicine, 333(24), 1581–1587. https://doi.org/10.1056/NEJM199512143332401 PubMed: PMID: 7477192
Toni, D., Ahmed, N., Anzini, A., Lorenzano, S., Brozman, M., Kaste, M., Mikulik, R., Putaala, J., & Wahlgren, N. (2012). Intravenous thrombolysis in young stroke patients: results from the SITS-ISTR. Neurology, 78(12), 880–887. https://doi.org/10.1212/WNL.0b013e31824d966b PubMed: PMID: 22402853
Tsivgoulis, G., Katsanos, A. H., Zand, R., Sharma, V. K., Köhrmann, M., Giannopoulos, S., Dardiotis, E., Alexandrov, A. W., Mitsias, P. D., Schellinger, P. D., & Alexandrov, A. V. (2017). Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis. Journal of Neurology, 264(6), 1227–1235. https://doi.org/10.1007/s00415-017-8520-1 PubMed: PMID: 28550481
Wang, X.-G., Zhang, L.-Q., Liao, X.-L., Pan, Y.-S., Shi, Y.-Z., Wang, C.-J., Wang, Y.-L., Liu, L.-P., Zhao, X.-Q., Wang, Y.-J., Li, D., & Wang, C.-X. (2015). Unfavorable Outcome of Thrombolysis in Chinese Patients with Cardioembolic Stroke: a Prospective Cohort Study. CNS Neuroscience & Therapeutics, 21(8), 657–661. https://doi.org/10.1111/cns.12421
Yamaguchi, T., Mori, E., Minematsu, K., Nakagawara, J., Hashi, K., Saito, I., & Shinohara, Y. (2006). Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke, 37(7), 1810–1815. https://doi.org/10.1161/01.STR.0000227191.01792.e3 PubMed: PMID: 16763187
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Florilyn Joyce C Bentrez
This work is licensed under a Creative Commons Attribution 4.0 International License.
